Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together with the immune-modulating activities of NC drugs suggest a potent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine 2015-06, Vol.13 (1), p.204-204, Article 204
Hauptverfasser:	Muraro, E, Comaro, E, Talamini, R, Turchet, E, Miolo, G, Scalone, S, Militello, L, Lombardi, D, Spazzapan, S, Perin, T, Massarut, S, Crivellari, D, Dolcetti, Riccardo, Martorelli, D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Immunity - drug effects Adjuvant treatment Adult Aged Aged, 80 and over Analysis Anthracyclines Antigens Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - immunology Cancer Care and treatment CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology Female Health aspects Humans Immunity, Innate - drug effects Immunophenotyping Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Lymphocytes Middle Aged Neoadjuvant Therapy NF-kappa B - metabolism Paclitaxel - pharmacology Paclitaxel - therapeutic use Patient outcomes Receptor, ErbB-2 - metabolism Remission Induction Trastuzumab - pharmacology Trastuzumab - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!